Novartis Home

At Novartis, we are reimagining medicine

Transmission electron microscopic image of an isolate from a case of COVID-19

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter

Live Magazine is now online

Our award-winning in-house magazine is now available in an engaging digital format.

Enter Magazine

Standing for Racial Equity and Justice as One Novartis

We believe unequivocally that Black Lives Matter. As a company focused on improving human health globally, we also recognize the disparities Black communities and communities of color face when it comes to healthcare.

Disclosure of Payments to Healthcare Professionals

Novartis publishes payments and other ‘transfers of value’ to Healthcare Professionals to increase transparency and build trust. Many countries disclose 2019 payments in June 2020.

Learn More

Novartis Home

At Novartis, we are reimagining medicine

Novartis COVID-19 Information Center

Live Magazine is now online

Standing for Racial Equity and Justice as One Novartis

Disclosure of Payments to Healthcare Professionals

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case

Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options